VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

Jun 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-06-01

Reporting Person: SACHS BRUCE I (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-01	Common Stock	A	2188	$0.00	Acquired	26339	Direct
2017-06-01	Common Stock	D	2941	—	Disposed	23398	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-01	Stock Option (Right to Buy)	$125.71	A	5295	Acquired	2027-05-31	Common Stock (5295)	Direct
2017-06-01	Deferred Stock Units	$	A	2941	Acquired		Common Stock (2941)	Direct

Footnotes

F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

F2: Upon the vesting of restricted stock units granted to Mr. Sachs on June 1, 2016, Mr. Sachs deferred the receipt of 2,941 shares of common stock and received instead 2,941 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Mr. Sachs is reporting the disposition of 2,941 shares of common stock in exchange for an equal number of deferred stock units.

F3: Fully vested.

F4: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.